Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 31

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 3
Chunk 31
---
/or Nolazol and/or the
Aexon platform that we may seek to develop in the future. Our ability to generate future revenues from product candidate sales depends
heavily on our success in many areas, including but not limited to:

  obtaining favorable results from and progress the pre-clinical and clinical development of our product candidates, namely Quilience and/or Nolazol;  

  developing and obtaining regulatory approval for registration studies protocols for our product candidates, namely Quilience and/or Nolazol;  

  subject to successful completion of registration and clinical trials of Quilience and/or Nolazol, applying for and obtaining marketing approval;  

  establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products, and at acceptable costs, to support market dem...  

  identifying, assessing, acquiring and/or developing new product candidates;  

  accurately identifying demand for our product candidates;  

  continued consumer interest in treatments to the symptoms of narcolepsy, IH, ADHD and Long-COVID;  

  obtaining market acceptance of our product candidates, if approved for marketing, as viable treatment options;  

  negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────

  obtaining and maintaining CIV labeling (no FDA imposed boxed warning, commonly referred to as a “ Black Box” warning) of our lead product candidate Quilience and follow-on product candidates, N...  

  establishing and nurturing relationships with the leading prescribers of narcolepsy, ADHD and Long-COVID prescriptions in the United States; and  

  attracting, hiring, and retaining qualified personnel.  

Alexander Zwyer, our Chief Executive Officer,
and Eric Konofal, our Chief Scientific Officer, have interests that may be different from, or in addition to, the interests of our shareholders
and the Company and Aexon may not have sufficient funds to continue or grow operations.

Alexander Zwyer owns 35% of
Aexon, and Eric Konofal owns 59% of Aexon. Mr. Konofal is the founder of Aexon, with which we have a license agreement, and also serves
as the President of Aexon. Mr. Zwyer holds no board or executive position at Aexon Labs, Inc., or Aexon. Mr. Zwyer and Mr.